Schulhoff & CO Inc Avadel Pharmaceuticals PLC Call Options Transaction History
Schulhoff & CO Inc
- $208 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVDL
# of Institutions
7Shares Held
738KCall Options Held
25KPut Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$11.3 Million3.61% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$9,4550.0% of portfolio
-
American Research & Management Co.100Shares$1,8910.0% of portfolio
-
Exane Derivatives33Shares$6240.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$180.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $1.15B
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...